問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

CHANGHUA CHRISTIAN HOSPITAL

List

789Cases

2007-03-01 - 2009-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2010-06-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Terminated1Sites

Study ended13Sites

2017-07-01 - 2018-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2016-03-02 - 2017-07-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2014-12-01 - 2016-12-31

Others

A Phase IIB-III, open-label, randomized, comparative study to assess the efficacy of ABX203 to maintain control of Hepatitis B disease after cessation of treatment with nucleos(t)ide analogs in adult HBeAg negative patients with chronic Hepatitis B in the Asia Pacific region

  • Condition/Disease

    chronic Hepatitis B

  • Test Drug

    ABX203

Participate Sites
12Sites

Terminated12Sites

2023-06-30 - 2024-01-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2022-11-01 - 2024-09-30

Phase I

An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

  • Condition/Disease

    Leukemia, Myeloid, Acute

  • Test Drug

    H3B-8800 (RVT-2001)

Participate Sites
5Sites

Recruiting5Sites

2010-11-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2011-06-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2010-11-01 - 2012-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

1 45 46 47 48 49 79
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB